Similar articles for PMID: 36137757

Year	Number of Results
2015	1
2016	4
2017	12
2018	15
2019	20
2020	14
2021	27
2022	28
2023	21
2024	0

1

PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.

Civan C, Kasper S, Berliner C, Fragoso-Costa P, Grünwald V, Pogorzelski M, Schaarschmidt BM, Lang S, Kersting D, Nader M, Lückerath K, Herrmann K, Fendler WP, Weber M. Civan C, et al. J Nucl Med. 2023 Mar;64(3):372-378. doi: 10.2967/jnumed.122.264342. Epub 2022 Sep 22. J Nucl Med. 2023. PMID: 36137757 Free PMC article.

2

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

3

Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.

Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.

4

Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.

5

Early molecular imaging response assessment based on determination of total viable tumor burden in [⁶⁸Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy.

Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. Rosar F, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725725 Free PMC article.

6

Clinical Translation and First In-Human Use of [⁴⁴Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.

Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F. Eppard E, et al. Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017. Theranostics. 2017. PMID: 29158832 Free PMC article.

7

Impact of [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [⁶⁸Ga]Ga-PSMA-11-PET/CT.

Groener D, Wichert J, Adams M, Mader N, Klimek K, Nguyen Ngoc C, Baumgarten J, Happel C, Mandel P, Chun FKH, Tselis N, Grünwald F, Sabet A. Groener D, et al. Cancers (Basel). 2023 Jul 30;15(15):3878. doi: 10.3390/cancers15153878. Cancers (Basel). 2023. PMID: 37568694 Free PMC article.

8

Examining Absorbed Doses of Indigenously Developed ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.

Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5. Cancer Biother Radiopharm. 2021. PMID: 32379495

9

Response assessment using ⁶⁸Ga-PSMA ligand PET in patients undergoing ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.

10

Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with ⁶⁸Ga-PSMA-11 PET/CT.

Kalshetty A, Menon B, Rakshit S, Bhattacharjee A, Basu S. Kalshetty A, et al. J Nucl Med Technol. 2021 Sep;49(3):235-240. doi: 10.2967/jnmt.120.261289. Epub 2021 Jul 9. J Nucl Med Technol. 2021. PMID: 34244223 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year